References
- Frankel SR, Baeuerle PA. Targeting t cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17(3):385-92; PMID:23623807; http://dx.doi.org/10.1016/j.cbpa.2013.03.029
- Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al. Tumor regression in cancer patients by very low doses of a t cell-engaging antibody. Science 2008; 321(5891):974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545
- Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S et al. Fda approval: Blinatumomab. Clin Cancer Res 2015; 21(18):4035-9; PMID:26374073; http://dx.doi.org/10.1158/1078-0432.CCR-15-0612
- Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al. Anti-cd20/cd3 t cell-dependent bispecific antibody for the treatment of b cell malignancies. Sci Transl Med 2015; 7(287):287ra270; PMID:25972002; http://dx.doi.org/10.1126/scitranslmed.aaa4802
- Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J et al. A novel, native-format bispecific antibody triggering t-cell killing of b-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943
- Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer WF, Lehmann S, Hofer T, Hosse RJ et al. A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors. Clin Cancer Res 2016 Jul 1; 22(13):3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
- Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR et al. The cea/cd3-bispecific antibody medi-565 (mt111) binds a nonlinear epitope in the full-length but not a short splice variant of cea. PLoS One 2012; 7(5):e36412; PMID:22574157; http://dx.doi.org/10.1371/journal.pone.0036412
- Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J et al. In vivo imaging of the activity of cea tcb, a novel t-cell bispecific antibody, reveals specific tumor targeting and fast induction of t-cell mediated tumor killing. Clin Cancer Res 2016 Apr 26; pii:clincanres.2622.2015. [Epub ahead of print]; PMID:27117182; http://dx.doi.org/10.1158/1078-0432.CCR-15-2622
- Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N et al. Therapeutic bispecific t-cell engager antibody targeting the intracellular oncoprotein wt1. Nat Biotechnol 2015; 33(10):1079-86; PMID:26389576; http://dx.doi.org/10.1038/nbt.3349
- Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C et al. Application of a mabel approach for a t cell bispecific monoclonal antibody: Cea tcb. J Immunother 2016 Jul 11; [Epub ahead of print]; PMID:27404941; http://dx.doi.org/10.1097/CJI.0000000000000132